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The Effects of Transforming Growth Factor-2
on Dopaminergic Graft Survival
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Ming H. Zheng,* and Gregory R. Stewart*
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Dopaminergic cell transplantation is a promising therapeutic approach for the treatment of Parkinson’s dis-
ease, the potential of which is limited due to poor survival and low dopamine content within engrafted
tissue. In this study, the ability of transforming growth factor-β2 (TGF-β2) to influence transplant survival
was evaluated. Cell suspensions containing fetal rat ventral mesencephalon (VM) cells were incubated prior
to surgery with vehicle (DPBS), varying concentrations of TGF-β2 (5–1000 ng/ml), or a pan-specific anti-
body against TGF-β (1D11, 100 ng/ml). VM cell suspensions (200,000 cells) were unilaterally implanted
into the striatum of adult Sprague-Dawley rats (n = 5–11 animals/group). Following a 3-week survival pe-
riod, small but viable VM grafts containing tyrosine hydroxylase-positive (TH+) neurons and fibers were
present in all animals. Addition of TGF-β2 resulted in a steep, bell-shaped dose–response curve with a
significant effect on TH+/dopamine cell survival. At 50 ng/ml TGF-β2, the number of surviving dopamine
neurons was increased twofold compared with controls. Addition of TGF-β2 or 1D11 did not significantly
influence graft volume. Further studies, possibly in combination with other neurotrophic factors, need to be
performed to obtain a greater understanding of the effects of TGF-β on dopamine neurons and fetal VM cell
engraftment.
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INTRODUCTION tissue (2,13,18,19,36,37,40,44,51,54); altering the physi-
cal properties of the graft or host (e.g., lowering the
Transplantation of dopamine (DA)-containing fetal body temperature of the graft recipient) (22); or optimiz-
ventral mesencephalon (VM) cells into the striatum is a ing the surgical procedure as in the micrografting ap-
promising treatment for Parkinson’s disease (5,11,15,20, proach described by Nikkhah et al. (39). In particular,
34,47). Numerous preclinical and clinical studies dem- the addition of trophic agents prior to, during, or after
onstrated survival and engraftment of dopamine neurons implant variably increased graft volume and/or dopa-
resulting in a significant improvement in parkinsonian mine cell survival (9).
symptoms (4,5,16,20,32). However, the potential of this Transforming growth factor-β (TGF-β) is part of a
therapy is limited, in part, due to the poor survival and large family of cytokines with pleiotropic effects on ani-
low content of dopamine neurons within the implant. mal and cell physiology, including wound healing, ex-
General estimates of cell survival are on the order of tracellular matrix regulation, modulation of inflamma-
10% (7–9,17,39), and careful dissection of the fetal VM tory cell infiltration, and immune modulation (33). TGF-
yields less than 5% dopamine neuron content within β exists as three isoforms in mammals (TGF-β1, 2, and
the cell suspension or tissue fragment used for implanta- 3) with varying and often complex effects on neural tis-
tion (10). sues (14,24,42,52). In the central nervous system (CNS),
A variety of methods have been evaluated aimed at TGF-β is a potent neurotrophic factor with direct influ-
increasing graft survival and dopamine content. These ences on cell growth, development, and differentiation.
include the addition of biologically active agents (such In vitro, TGF-β2 regulates the survival of DA neurons
as cytoprotectants and neurotrophic factors) to transplant (26,41), and protects against toxin-induced degeneration
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(23,25). Although there is considerable evidence that to approximately 95%. Anti-TGF-β antibody, 1D11, was
produced at Genzyme as a monoclonal IgG1 antibody inTGF-β exerts powerful neurotrophic and neuropro-
tective effects on DA neurons in culture, the effect of SP2/0 myeloma cells and purified on a protein G column
to 95% as assessed by SDS-PAGE.TGF-β on DA survival in vivo has not been investigated
to date.
Based on these neurotrophic and neuroprotective prop- Transplantation
erties, this study investigated whether TGF-β2 could en- Animals were anesthetized with ketamine/xylazinehance dopaminergic graft survival. VM cell suspensions (±diazepam) and the head mounted in a stereotaxic
were preincubated with TGF-β2 across a wide range of frame. Two deposits (1 µl each) of VM cell suspension
concentrations (5–1000 ng/ml), vehicle control, or 1D11,
were injected into the right striatum (coordinates: A/P:
a pan-specific antibody to TGF-β, and then implanted
+1.0, M/L: −2.5, D/V: −4.5 and −5.5 mm, from bregma)into the nonlesioned rat striatum. Following a 3-week
at a rate of 0.2 µl/min through a 26-gauge needle
survival, the influence of pretreatments on graft volume
attached to a Hamilton syringe (200,000 total cell dose).
and dopamine content was investigated. The needle was left in place for 10 min after the second
injection, then slowly withdrawn. Animals (n = 5–11/MATERIALS AND METHODS
group) were assigned to one of eight groups based onExperimental Animals pretreatment of cells with TGF-β2, 1D11, or vehicle (sa-
Adult male and female Sprague-Dawley rats (Ta- line) as described above. Animals were transplanted
conic, Germantown, NY) were housed under 12:12-h over the course of several different surgical days. A
light/dark cycle and provided food and water ad libitum. combination of experimental doses and vehicle treat-
All procedures were carried out under an approved ments was used on each day to counterbalance any bias
IACUC protocol and in accordance with guidelines for on graft results for a given surgical session.
the use of animals in research (38).
HistologyPreparation of Fetal Ventral Mescencephalic
Cell Suspension At 20 days postimplantation, animals were deeply an-
esthetized and transcardially perfused with phosphate-The floor of the VM was isolated from E14 rat em-
buffered 2% paraformaldehyde/0.03% glutaraldehyde.bryos (day of mating counted as day 0). The VMs were
The brains were removed and postfixed for 48 h. Serialdissected in Ca2+- and Mg2+-free Dulbecco’s phosphate
coronal sections were cut on a vibratome or cryostat atbuffered saline (DPBS) and incubated in 0.05% trypsin-
a 50-µm thickness. Brains cut with a cryostat were pro-EDTA for 10 min. The VM tissue was then washed in
tected in sucrose prior to freezing. Two series of free-Hanks buffered salt solution (HBSS) containing 50 µg/
floating sections (spaced 300 µm apart), spanning theml human recombinant DNase and dissociated by using
rostro-caudal extent of the striatum, were set aside fora three-step trituration process. Tissue was passed through
staining. The first series was washed in 0.1 M potassiumthree precalibrated Pasteur pipettes with decreasingly
phosphate buffer saline (kPBS) and preincubated in 5%smaller apertures (1, 0.7, and 0.5 mm), resulting in a
normal goat serum (NGS) and 0.25% Triton X-100 insingle cell suspension. VM cell suspensions were centri-
kPBS for 3 h. Sections were then incubated overnight infuged at 1000 rpm for 5 min at room temperature (RT),
kPB containing a polyclonal antibody to tyrosine hy-resuspended in sterile Ca2+- and Mg2+-free DPBS, and
droxylase (TH, 1:4000; Pel-Freez), 5% NGS, and 0.2%stored overnight at 4°C prior to transplant. Cell viability
Triton X-100 at 4°C. The sections were rinsed in kPBwas checked the next morning and averaged 93% using
and incubated for 1 h in a biotinylated goat anti-rabbittrypan blue dye. One to four hours prior to surgery,
IgG (1:200 diluted in 0.1% BSA, 0.1% Triton X-100 inTGF-β2 (5, 10, 50, 100, 500, or 1000 ng/ml), 1D11 (100
kPBS; Vector Labs). The tissue was rinsed in kPB andng/ml, a pan-specific antibody to TGF-β), or vehicle
incubated in peroxidase-conjugated avidin-biotin com-alone (DPBS) was added to the cell suspension, and fi-
plex (1:50 diluted in 0.1% BSA, 0.1% Triton X-100 innal cell density was adjusted to 100,000 viable cells/µl
kPBS; Vector Labs) for 1 h at room temperature. Anti-using DPBS. The VM cell suspensions, containing the
body binding was visualized by reaction of the sectionsvarying concentrations of TGF-β, vehicle, or 1D11 were
with 3′,3′-diaminobenzidine and hydrogen peroxide.then used for transplantation.
Stained sections were mounted on gel-coated slides, de-
Test Materials hydrated, and coverslipped. The second series of sec-
tions through each graft was mounted on gel-coatedRecombinant human TGF-β2 (100 mg/ml) was pro-
duced at Genzyme in Chinese hamster ovary cells and slides, stained for hematoxylin and eosin (H&E), dehy-
drated, and coverslipped.purified on cation exchange and reversed phase columns
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Quantitative Graft Histology rons was significantly different, F(7, 44) = 3.0849, p <
0.0098. Pretreatment with TGF-β2 yielded a steep, bell-Slides were read under blinded conditions for all
shaped dose–response curve in relation to graft TH+ cellquantitative analysis. The number of TH+ neurons pres-
content, with a maximal effect at 50 ng/ml (Fig. 3).ent within the entire boundaries of the graft (including
Compared with the saline control, the number of TH+cells that effluxed into the corpus callosum and cortex)
cells in the 50 ng/ml TGF-β2 group was increasedfor each section was counted at 20× magnification under
roughly twofold (203 ± 32 vs. 390 ± 105, p < 0.0048).brightfield microscopy and recorded. The total number
The number of TH+ graft neurons in the 10 ng/ml TGF-of TH+ cells/graft was estimated by multiplying cell β2 group was increased (nonsignificantly) by 20% overcounts by 6; every sixth section was stained and counted
saline control. All other TGF-β2 treatment groups hadthrough the graft. Counts were corrected using Aber-
mean TH+ cell counts that fell below control values, butcrombie’s formula (1) (cell diameter = 40 µm, section
none of these group comparisons reached significance.thickness = 50 µm). Graft area was measured in TH+
There was no effect of pretreatment of cells with anti-stained tissue sections as margins were easily distin-
TGF-β antibody, 1D11, on TH+ cell counts. Across allguished between transplanted cells and displaced host
engrafted animals, there was a significant, positive cor-tissue. The graft outline was traced from digital images
relation between the number of TH+ cells and graft vol-acquired using a SPOT camera interfaced with a com-
ume (r = 0.547, p < 0.05) independent of treatment group.puter. Area (mm2) was determined using the SCION Im-
However, TH cell density (TH count/graft volume) wasage program (ported from NIH Image for the Macintosh
significantly (p < 0.0002) increased in the 50 ng/mlby Scion Corporation and available on the Internet at
group, consistent with a selective effect of TGF-β2 onhttp://www.scioncorp.com). Graft volume (mm3) was then
dopamine survival postimplant.estimated as the sum of the graft areas multiplied by the
distance between sections. The results for TH+ cell DISCUSSION
counts and graft volume were calculated as means ±
Neural transplantation, as a form of dopamine cellSEM. Each set of data was subjected to one-way analy-
replacement therapy for Parkinson’s disease, has yieldedsis of variance (ANOVA) and a Fischer LSD post hoc
encouraging results in preclinical models as well as in atest.
limited series of human cases (5,11,15,20,34,47). How-
ever, these early gains have been tempered by a growingRESULTS
perception that clinically meaningful engraftment on aGeneral Graft Histology large scale awaits significant improvements in transplan-
Small, but viable, grafts were present in all 52 im- tation technology. The two most notable technical short-
planted animals. Grafts typically were compact, rounded comings are relatively poor cell survival and low dopa-
or elongate clusters of cells that displaced host striatal mine cell content. In response, a large effort has been
tissue (Fig. 1A). Grafted cells were often found extend- generated in preclinical models investigating methods to
ing dorsally along the injection tract with a small sec- improve suboptimal engraftment including trophic sup-
ondary deposit in the corpus callosum and deeper layers plementation of grafted tissues and cells.
of the overlying cortex. By H&E staining, grafts were Within this context, the present study evaluated graft
populated by large, rounded cells that were well inte- augmentation through the addition of TGF-β2 to the VM
grated, having indistinct margins with the host brain cell suspension prior to transplant. TGF-β was not eval-
(Fig. 1B). Scattered macrophages were present along the uated previously in this model despite considerable evi-
injection tract in some animals, but there was no evi- dence that it has potent developmental, neurotrophic,
dence of vascular cuffing or small cell infiltration sug- and neuroprotective effects on midbrain dopamine neu-
gestive of graft rejection. Graft size was fairly uniform rons. Across a wide range of concentrations (5–1000 ng/
across experimental groups (Fig. 2) with an average vol- ml), TGF-β2 yielded a maximal survival effect at 50 ng/
ume of 0.679 ± 0.130 mm3 (±SEM). There was no sig- ml with roughly a twofold increase in cell numbers over
nificant effect of TGF-β2 pretreatment on graft volume, vehicle-treated animals. This magnitude of effect is
F(7, 44) = 0.689, p ≤ 0.6805. comparable to numerous other factors previously used
to supplement grafted tissue (9). However, grafts in the
TH Cell Survival present study were small with relatively low numbers of
surviving TH+ cells. The effects of TGF-β2 on dopa-Densely stained TH+ cells and fibers were present to
varying degrees within all grafts. TH+ cells were typi- minergic survival should be interpreted with caution
pending further study of the molecule on larger grafts,cally dispersed along the outer margins with TH+ fibers
and isolated cell bodies extending through the interior possibly in combination with 6-OHDA denervation of
the host striatum (see below). Nevertheless, the effective(Fig. 1C, D). Across all groups, the number of TH+ neu-
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Figure 1. Photomicrographs of VM graft histology. H&E staining with views of a typical striatal VM graft (50 ng/ml TGF-β2) at
low (A) and higher magnification (B) showing good survival and integration within the host brain. TH staining of the same graft
at low (C) and higher magnification (D) showing robust cell and fiber staining within the graft.
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Figure 2. VM graft volume (mm3 ± SEM) across treatment groups. Graft size was fairly uniform and there were no significant
differences in volume between groups.
concentration range of 10–50 ng/ml on TH survival in quent engraftment. The concentration of 1D11 used in
this study (100 ng/ml) is known to completely inhibitvivo for TGF-β2 compares favorably with its in vitro
activity. We found that concentrations of TGF-β2 as low TGF-β activity using in vitro assays (48).
To date, multiple transplant approaches have beenas 20 ng/ml significantly increased the survival of dopa-
mine neurons within VM cultures (personal observa- used, making it difficult to compare the efficacy of graft
supplements on TH cell survival. This study used a typi-tion). Other investigators have also reported that TGF-
β2 in this concentration range increased dopamine cell cal cell “dose” of 200,000 cells/implant, and implan-
tation was made into normal striatum as opposed tosurvival in vitro (23,25,26,41).
At concentrations of TGF-β2 greater than 50 ng/ml, striatum denervated of dopaminergic innervation by 6-
hydroxydopamine. It remains unclear if the denervatedthe beneficial effects on TH cell survival in VM grafts
were lost, suggesting that there may be an optimal con- striatum is a more appropriate environment in which to
evaluate graft survival (46,49). Lesion-induced changescentration of TGF-β/receptor occupancy required for
efficacy. This kind of dose–response curve is also seen in endogenous trophic expression within host striatum
could influence the effect of TGF-β on subsequent THin other aspects of TGF-β biology. For example, neutro-
phil and eosinophil chemotaxis show a similar bell- cell survival within the VM grafts.
While the action of TGF-β on nervous tissue is oftenshaped response (35,43). The results highlight that cell
survival in response to a “simple” additive may be quite characterized as neurotrophic-like, it is clear that it has
a more complex biological relationship with the nervouscomplex (more may not be better) and underscores the
need to do rigorous dose–response testing. Though no system (31). In particular, several studies by Krieglstein
et al. (24,27,29) demonstrated that the main activity ofbenefit was demonstrated, extremely high concentra-
tions of TGF-β2 (up to 1000 ng/ml) did not have a dele- TGF-β may be to regulate the relative potency of other
neurotrophic factors. In vitro, the addition of TGF-β2terious effect on graft survival or host brain. Likewise,
addition of a pan-specific antibody to TGF-β (1D11) to (as well as TGF-β3) synergistically increased trophic ac-
tivity of CNTF, GDNF, and FGF-2 (28–30,53). In somethe VM cell suspension had no apparent effect on subse-
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Figure 3. TH-positive cell content (mean ± SEM) for VM grafts across treatment groups. Preincubation of VM cells with varying
concentrations of TGF-β2 resulted in a steep dose–response curve for TH cell counts. The only significant difference, F(7, 44) =
3.0849, p < 0.0098, was a twofold increase in survival in VM cells pretreated with 50 ng/ml TGF-β2 compared with controls. The
asterisk (*) denotes significance.
cases (e.g., chick ciliary ganglion cultures), TGF-β was transplant when tissues were incubated in growth factors
for 2 h before transplant. In the present study, followingfound to have no survival-promoting effects unless
it was co-incubated with another trophic factor (28). 3-week survival, dopaminergic morphology had taken
on a fairly mature appearance with elaboration of pro-Subsequent transplant experiments should investigate
whether incubating cells with cocktails of TGF-β2 and cesses and the presence of large TH+ cells along the
periphery of the VM graft or clustered within the inte-GDNF or other factors will act synergistically to in-
crease cell survival and engraftment. rior. This length of survival is well past the critical pe-
riod of cell death, and similar studies on trophic supple-The window of opportunity for manipulating grafts
extends from initial dissection of donor tissue to chronic mentation have used time points in the range of 2–8
weeks.treatment of the host following implantation. Previous
studies found that the majority of cell death occurs dur- An exciting new advancement in transplant technol-
ogy is the use of stem cells, particularly neural steming mechanical dissociation of VM tissue or within the
first few days following transplant (3,6,12,21,49,50,55). cells (45). The ability to culture and expand a cell source
for transplantation offers significant advantages over theIn this study, TGF-β2 was added to the cell suspension
a few hours prior to transplant. This was considered a use of freshly derived tissue. Culturing of cells allows
for in vitro manipulation, and already a tremendous ef-simple, practical, clinically relevant way to provide tro-
phic supplementation immediately prior to and during fort has been directed at ways to induce and enrich for
dopaminergic phenotype in neural stem cells. Here, too,the initial engraftment period, which is a critical period
of cell death for dopamine neurons. An earlier study by the multiple activities of TGF-β, as a developmental fac-
tor, a trophic regulator, and possibly a differentiatingZawada et al. (55) demonstrated increased numbers of
TH+ cells and reduced apoptotic profiles at 24 h post- agent, should be carefully assessed.
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